The Center for Proteomics develops methods to help clarify the biological mechanisms associated with toxicity using mass spectrometry-based proteomics. The development of mechanisms to integrate proteomic data with that of other omics data is underway. This work complements the development of software for large-scale protein identification studies and is being extended to assist in quantitative comparisons. This work is necessary to permit a higher sample number to be examined to permit both dose and time studies in support of toxicology studies. Initial work focused on improvements in throughput and sensitivity of mass spectrometry-based proteomic experiments, as well as the development of bioinformatics to handle the large volume of data that are generated.

Contact Information

For more information, please contact Dr. James Fuscoe, at 870-543-7126 or james.fuscoe@fda.hhs.gov